Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/NUVAXOVID DISPERSION INYECTABLE

Approved

STANDARD

NUVAXOVID DISPERSION INYECTABLE

Novavax Cz A.S.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 3, 2022
Approval ID: 4e9a36bf95c9712e
Company: Novavax Cz A.S.
Type: Standard

Approval Details

Approval Id: 4e9a36bf95c9712e
Drug Cima Aemps Name: NUVAXOVID DISPERSION INYECTABLE
Register Number: 1211618001
Holder Company Name: Novavax Cz A.S.
Marketing Company Name: Sanofi Aventis S.A.
Holder Company Detail Path: /organization/novavax-cz-a-s
Authorization Date: 2022-02-03
Dosage Form: DISPERSIÓN INYECTABLE
Dose: 0,5 ml
Route Of Administration: VÍA INTRAMUSCULAR
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Novavax Cz A.S.
Company Detail Path: /organization/novavax-cz-a-s

Company Information

Pharmaceutical Company Name: NOVAVAX CZ a.s.
Country Name: Czech Republic
City Name: praha,hlavní město praha,country_cz
Address: Líbalova 2348/1

Active Ingredients

VACUNA DE PROTEINA RECOMBINANTE DE LA ESPICULA FRENTE A COVID-19 (NOVAVAX)

5 µg/pulsación

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 3, 2022

Approval ID

4e9a36bf95c9712e

Type

Standard

Back to CIMA-AEMPS Approvals

NUVAXOVID DISPERSION INYECTABLE - CIMA-AEMPS Drug Approval Details